VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs VLX 1570 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Vivolux
- 03 Oct 2017 This trial has been discontinued in Finland (End date: 2017-09-18).
- 01 Jun 2017 Planned number of patients changed from 65 to 70.
- 01 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.